Anacor Pharmaceuticals

Anacor Pharmaceuticals company information, Employees & Contact Information

Anacor was a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.

Company Details

Employees
33
Founded
-
Address
1020 East Meadow Circle, Palo Alto,ca 94303-4230,united States
Phone
(650) 543-7500
Email
in****@****cor.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
anacor.com
HQ
Palo Alto, CA
Looking for a particular Anacor Pharmaceuticals employee's phone or email?

Anacor Pharmaceuticals Questions

News

Pfizer Completes Anacor Acquisition - CHEManager

Pfizer Completes Anacor Acquisition CHEManager

(PDF) Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis - researchgate.net

(PDF) Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis researchgate.net

Tavaborole Approved by DFA For Treatment Of Onychomycosis of the Toenails - Fierce Biotech

Tavaborole Approved by DFA For Treatment Of Onychomycosis of the Toenails Fierce Biotech

Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel - Reuters

Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel Reuters

Pfizer completes acquisition of Anacor Pharmaceuticals - European Pharmaceutical Review

Pfizer completes acquisition of Anacor Pharmaceuticals European Pharmaceutical Review

Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion (Published 2016) - The New York Times

Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion (Published 2016) The New York Times

Pfizer wins quick reward from buyout of Anacor with approval of eczema drug expected to be blockbuster - Fierce Pharma

Pfizer wins quick reward from buyout of Anacor with approval of eczema drug expected to be blockbuster Fierce Pharma

Pfizer to buy Anacor for eczema ointment - Chemistry World

Pfizer to buy Anacor for eczema ointment Chemistry World

Pfizer to acquire Anacor - Chemical & Engineering News

Pfizer to acquire Anacor Chemical & Engineering News

First-in-Class Antifungal Available for Toenail Onychomycosis - Medical Professionals Reference

First-in-Class Antifungal Available for Toenail Onychomycosis Medical Professionals Reference

Pfizer to buy Anacor in $5.2bn deal for access to eczema gel - The Guardian

Pfizer to buy Anacor in $5.2bn deal for access to eczema gel The Guardian

Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why - Fox Business

Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why Fox Business

Anacor Pharmaceuticals and MMV sign agreement to pursue promising compound for malaria - Medicines for Malaria Venture

Anacor Pharmaceuticals and MMV sign agreement to pursue promising compound for malaria Medicines for Malaria Venture

Pfizer To Buy Anacor Pharmaceuticals For $5.2B - International Business Times

Pfizer To Buy Anacor Pharmaceuticals For $5.2B International Business Times

AN2 upsizes IPO, teeing up bid to revitalize antibiotic let go by GSK and Pfizer - Fierce Biotech

AN2 upsizes IPO, teeing up bid to revitalize antibiotic let go by GSK and Pfizer Fierce Biotech

Pfizer to buy toenail fungus treatment maker Anacor for $5bn - The Telegraph

Pfizer to buy toenail fungus treatment maker Anacor for $5bn The Telegraph

Pfizer's Anacor deal showcases new wave of eczema therapies - The Himalayan Times

Pfizer's Anacor deal showcases new wave of eczema therapies The Himalayan Times

Top Anacor Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant